Scientific Reports (Dec 2020)

Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19

  • Marthe Jøntvedt Jørgensen,
  • Jan Cato Holter,
  • Erik Egeland Christensen,
  • Camilla Schjalm,
  • Kristian Tonby,
  • Søren Erik Pischke,
  • Synne Jenum,
  • Linda G. Skeie,
  • Sarah Nur,
  • Andreas Lind,
  • Hanne Opsand,
  • Tone Burvald Enersen,
  • Ragnhild Grøndahl,
  • Anne Hermann,
  • Susanne Dudman,
  • Fredrik Muller,
  • Thor Ueland,
  • Tom Eirik Mollnes,
  • Pål Aukrust,
  • Lars Heggelund,
  • Aleksander Rygh Holten,
  • Anne Ma Dyrhol-Riise

DOI
https://doi.org/10.1038/s41598-020-78710-7
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 11

Abstract

Read online

Abstract In SARS-CoV-2 infection there is an urgent need to identify patients that will progress to severe COVID-19 and may benefit from targeted treatment. In this study we analyzed plasma cytokines in COVID-19 patients and investigated their association with respiratory failure (RF) and treatment in Intensive Care Unit (ICU). Hospitalized patients (n = 34) with confirmed COVID-19 were recruited into a prospective cohort study. Clinical data and blood samples were collected at inclusion and after 2–5 and 7–10 days. RF was defined as PaO2/FiO2 ratio (P/F) < 40 kPa. Plasma cytokines were analyzed by a Human Cytokine 27-plex assay. COVID-19 patients with RF and/or treated in ICU showed overall increased systemic cytokine levels. Plasma IL-6, IL-8, G-CSF, MCP-1, MIP-1α levels were negatively correlated with P/F, whereas combinations of IL-6, IP-10, IL-1ra and MCP-1 showed the best association with RF in ROC analysis (AUC 0.79–0.80, p < 0.05). During hospitalization the decline was most significant for IP-10 (p < 0.001). Elevated levels of pro-inflammatory cytokines were present in patients with severe COVID-19. IL-6 and MCP-1 were inversely correlated with P/F with the largest AUC in ROC analyses and should be further explored as biomarkers to identify patients at risk for severe RF and as targets for improved treatment strategies.